{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:52:53Z","timestamp":1773532373269,"version":"3.50.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.toxicon.2018.04.002","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T12:58:34Z","timestamp":1522760314000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["What can be learned in the snake antivenom field from the developments in human plasma derived products?"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0507-9243","authenticated-orcid":false,"given":"Thierry","family":"Burnouf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2018.04.002_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1423-0410.1962.tb03240.x","article-title":"Intravenous administration of human gamma-globulin","volume":"7","author":"Barandun","year":"1962","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.transci.2017.04.001","article-title":"Immunoglobulin G levels during collection of large volume plasma for fractionation","volume":"56","author":"Burkhardt","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.toxicon.2018.04.002_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0378-4347(94)00532-A","article-title":"Chromatography in plasma fractionation: benefits and future trends","volume":"664","author":"Burnouf","year":"1995","journal-title":"J.\u00a0Chromatogr. B Biomed. Appl."},{"key":"10.1016\/j.toxicon.2018.04.002_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"Burnouf","year":"2007","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.toxicon.2018.04.002_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1423-0410.2010.01384.x","article-title":"Recombinant plasma proteins","volume":"100","author":"Burnouf","year":"2011","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/voxs.12099","article-title":"New approaches for manufacturing plasma derivatives","volume":"9","author":"Burnouf","year":"2014","journal-title":"ISBT Sci. Ser."},{"key":"10.1016\/j.toxicon.2018.04.002_bib7","first-page":"4","article-title":"New developments in plasma derivatives production","volume":"109","author":"Burnouf","year":"2015","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1365-2516.2008.01797.x","article-title":"Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems","volume":"14","author":"Burnouf","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.toxicon.2018.04.002_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biologicals.2004.07.001","article-title":"Assessment of the viral safety of antivenoms fractionated from equine plasma","volume":"32","author":"Burnouf","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev."},{"key":"10.1016\/j.toxicon.2018.04.002_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0165-022X(01)00221-4","article-title":"Affinity chromatography in the industrial purification of plasma proteins for therapeutic use","volume":"49","author":"Burnouf","year":"2001","journal-title":"J.\u00a0Biochem. Biophys. Methods"},{"key":"10.1016\/j.toxicon.2018.04.002_bib12","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2516.2003.00701.x","article-title":"Nanofiltration of plasma-derived biopharmaceutical products","volume":"9","author":"Burnouf","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.toxicon.2018.04.002_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.biologicals.2006.11.003","article-title":"Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms","volume":"35","author":"Burnouf","year":"2007","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib14","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/btpr.1758","article-title":"Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process","volume":"29","author":"Caricati","year":"2013","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.toxicon.2018.04.002_bib15","series-title":"EMA\/CHMP\/BWP\/3354\/1999 rev.1","article-title":"Guideline on production and quality control of animal immunoglobulins and immunosera for human use","author":"CHMP","year":"2016"},{"key":"10.1016\/j.toxicon.2018.04.002_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1172\/JCI101508","article-title":"Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma","volume":"23","author":"Cohn","year":"1944","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.toxicon.2018.04.002_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.toxicon.2018.04.002_bib18","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1537-2995.1986.26587020113.x","article-title":"Hemolysis following intravenous immune globulin therapy","volume":"26","author":"Copelan","year":"1986","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1537-2995.1986.26587020113.x","article-title":"Hemolysis following intravenous immune globulin therapy","volume":"26","author":"Copelan","year":"1986","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00919386","article-title":"Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies","volume":"13","author":"Cunningham-Rundles","year":"1993","journal-title":"J.\u00a0Clin. Immunol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/biol.2002.0332","article-title":"Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution","volume":"30","author":"Dichtelmuller","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib22","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/j.1537-2995.2009.02222.x","article-title":"Robustness of solvent\/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies","volume":"49","author":"Dichtelm\u00fcller","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib23","article-title":"Transfusion-transmitted infections","volume":"153","author":"Dodd","year":"2017","journal-title":"Pract. Transfus. Med."},{"key":"10.1016\/j.toxicon.2018.04.002_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0041-0101(89)90177-3","article-title":"Purification of F(ab')2 anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield","volume":"27","author":"dos Santos","year":"1989","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.04.002_bib25","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/j.1537-2995.2012.03868.x","article-title":"Immunoglobulin therapy and thrombosis: coincidence or causation?","volume":"52","author":"Drelich","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib26","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1111\/j.1365-2516.2011.02511.x","article-title":"Pharmacokinetic study of minipooled solvent\/detergent-filtered cryoprecipitate factor VIII","volume":"17","author":"El-Ekiaby","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.toxicon.2018.04.002_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-3148.2009.00963.x","article-title":"Solvent-detergent filtered (S\/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system","volume":"20","author":"El-Ekiaby","year":"2010","journal-title":"Transfus. Med."},{"key":"10.1016\/j.toxicon.2018.04.002_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003501","article-title":"Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries","volume":"9","author":"El-Ekiaby","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.toxicon.2018.04.002_bib29","series-title":"Plasma Master File -","author":"EMA","year":"2018"},{"key":"10.1016\/j.toxicon.2018.04.002_bib30","first-page":"583","article-title":"Safety issues of plasma-derived products for treatment of inherited bleeding disorders","author":"Farrugia","year":"2016","journal-title":"Seminars Thrombosis Hemost."},{"key":"10.1016\/j.toxicon.2018.04.002_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/j.1875-9114.1987.tb03512.x","article-title":"Methodology and safety considerations in the production of an intravenous immunoglobulin preparation","volume":"7","author":"Friedli","year":"1987","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.toxicon.2018.04.002_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/vox.12025","article-title":"Thromboembolic events associated with immunoglobulin treatment","volume":"105","author":"Funk","year":"2013","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-016-0192-3","article-title":"Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A-and B-specific immunoaffinity chromatography: industry-scale assessment","volume":"30","author":"Gerber","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.toxicon.2018.04.002_bib34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-016-0192-3","article-title":"Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: industry-scale assessment","volume":"30","author":"Gerber","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.toxicon.2018.04.002_bib35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biologicals.2014.04.002","article-title":"Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products","volume":"42","author":"Germishuizen","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40259-017-0222-9","article-title":"Biological safety of a highly purified 10% liquid intravenous immunoglobulin preparation from human plasma","volume":"31","author":"Goussen","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.toxicon.2018.04.002_bib37","first-page":"2446","article-title":"Polyvalent horse F(Ab ')(2) snake antivenom: development of process to produce polyvalent horse F(Ab ')(2) antibodies anti-african snake venom","volume":"9","author":"Guidlolin","year":"2010","journal-title":"Afr. J. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib38","doi-asserted-by":"crossref","first-page":"17063","DOI":"10.1038\/nrdp.2017.63","article-title":"Snakebite envenoming","volume":"3","author":"Guti\u00e9rrez","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.toxicon.2018.04.002_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.toxicon.2006.09.005","article-title":"Strengthening antivenom production in Central and South American public laboratories: report of a workshop","volume":"49","author":"Gutierrez","year":"2007","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.04.002_bib40","series-title":"Animal Toxins: State of the Art. Perspectives in Health and Biotechnology","first-page":"393","article-title":"Snake Antivenoms. Technological, clinical and public health issues","author":"Guti\u00e9rrez","year":"2009"},{"key":"10.1016\/j.toxicon.2018.04.002_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.biologicals.2011.02.005","article-title":"Antivenoms for the treatment of snakebite envenomings: the road ahead","volume":"39","author":"Gutierrez","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib42","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.iac.2008.06.002","article-title":"Intravenous immunoglobulins: evolution of commercial IVIG preparations","volume":"28","author":"Hooper","year":"2008","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"10.1016\/j.toxicon.2018.04.002_bib43","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1537-2995.1985.25686071422.x","article-title":"Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations","volume":"25","author":"Horowitz","year":"1985","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2011.07.005","article-title":"Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases","volume":"25","author":"Hsu","year":"2011","journal-title":"Infect. Dis. Clin. North Am."},{"key":"10.1016\/j.toxicon.2018.04.002_bib45","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1371\/journal.pmed.0050218","article-title":"The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths","volume":"5","author":"Kasturiratne","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.toxicon.2018.04.002_bib46","first-page":"997","article-title":"Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma","volume":"18","author":"Kim","year":"2008","journal-title":"J.\u00a0Microbiol. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1423-0410.1962.tb03274.x","article-title":"Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib48","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/trf.12423","article-title":"Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates","volume":"54","author":"Klamroth","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/biol.2002.0334","article-title":"Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates","volume":"30","author":"Korneyeva","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.tracli.2017.06.020","article-title":"Fifteen years of nucleic acid testing in France: results and lessons","author":"Laperche","year":"2017","journal-title":"Transfus. Clinique Biol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib51","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/biol.2002.0335","article-title":"Inactivation of West-Nile virus during peptic cleavage of horse plasma IgG","volume":"30","author":"Lazar","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1423-0410.2003.00285.x","article-title":"Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography","volume":"84","author":"Lebing","year":"2003","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1046\/j.1423-0410.2002.00241.x","article-title":"Purification of human immunoglobulin G: a new approach to plasma fractionation","volume":"83","author":"Li","year":"2002","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib54","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nbt0298-190","article-title":"Design, synthesis, and application of a protein A mimetic","volume":"16","author":"Li","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2005.01.032","article-title":"Use of intravenous immunoglobulin G (IVIG)","volume":"19","author":"Looney","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/biol.1994.1003","article-title":"Inactivation of hepatitis C virus in low pH intravenous immunoglobulin","volume":"22","author":"Louie","year":"1994","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib57","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1093\/clinids\/8.Supplement_4.S374","article-title":"Three generations of immunoglobulin G preparations for clinical use","volume":"8","author":"McCue","year":"1986","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.toxicon.2018.04.002_bib58","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1081-1206(10)60197-4","article-title":"Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century","volume":"101","author":"Moore","year":"2008","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biologicals.2007.02.004","article-title":"Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins","volume":"35","author":"Mpandi","year":"2007","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib60","first-page":"169","article-title":"Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation","volume":"81","author":"Nowak","year":"1993","journal-title":"Dev. Biol. Stand"},{"key":"10.1016\/j.toxicon.2018.04.002_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2016.11.002","article-title":"A\u00a0new manufacturing process to remove thrombogenic factors (II, VII, IX, X, and XI) from intravenous immunoglobulin gamma preparations","volume":"45","author":"Park","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib62","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib63","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/9781119013020.ch55","article-title":"Testing for pathogens in donors","author":"Pham","year":"2016","journal-title":"Rossi's Princ. Transfus. Med."},{"key":"10.1016\/j.toxicon.2018.04.002_bib64","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.toxicon.2018.04.002_bib65","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1537-2995.1975.15476034548.x","article-title":"Cryoprecipitate quality and supply","volume":"15","author":"Pool","year":"1975","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.tracli.2015.12.004","article-title":"Nouveaux risques viraux en transfusion sanguine \u00e0 l\u2019horizon 2016","volume":"23","author":"Pozzetto","year":"2016","journal-title":"Transfus. Clinique Biol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jim.2003.07.014","article-title":"Fractionation of equine antivenom using caprylic acid precipitation in combination with cationic ion-exchange chromatography","volume":"282","author":"Raweerith","year":"2003","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.toxicon.2018.04.002_bib69","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0041-0101(94)90087-6","article-title":"Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production","volume":"32","author":"Rojas","year":"1994","journal-title":"Toxicon"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.toxicon.2018.04.002_bib70","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1111\/trf.13115","article-title":"Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products","volume":"55","author":"Romberg","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib71","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.2174\/1381612822666160831103806","article-title":"Subcutaneous immunoglobulins: a promising alternative for immunomodulation?","volume":"22","author":"Sanchez-Ramon","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.toxicon.2018.04.002_bib72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-3038.1994.tb00222.x","article-title":"Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action","volume":"5","author":"Schiff","year":"1994","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2009.05.003","article-title":"Assessment of the impact of solvent\/detergent treatment on the quality and potency of a whole IgG equine antivenom","author":"Segura","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/trf.12280","article-title":"Assessment of immunoglobulin concentrates on thrombogenic activity by thrombin generation assay, prekallikrein activator assay, and size-exclusion chromatography","volume":"54","author":"Seifner","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.toxicon.2018.04.002_bib75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.biologicals.2011.11.006","article-title":"Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation","volume":"40","author":"Solano","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.toxicon.2018.04.002_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","article-title":"On the dark side of therapies with immunoglobulin concentrates: the adverse events","volume":"6","author":"Spath","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.toxicon.2018.04.002_bib77","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0003-9861(69)90285-9","article-title":"The isolation of IgG from mammalian sera with the aid of caprylic acid","volume":"134","author":"Steinbuch","year":"1969","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.toxicon.2018.04.002_bib78","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.toxicon.2018.04.002_bib79","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0378-4347(97)00319-8","article-title":"Characterisation of a chromatographically produced anti-D immunoglobulin product","volume":"700","author":"Stucki","year":"1997","journal-title":"J.\u00a0Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.toxicon.2018.04.002_bib80","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0041-0101(02)00393-8","article-title":"Report of a WHO workshop on the standardization and control of antivenoms","volume":"41","author":"Theakston","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2018.04.002_bib81","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1423-0410.1999.7610055.x","article-title":"Anti-Rh D activity of commercial intravenous immunoglobulin preparations","volume":"76","author":"Turner","year":"1999","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib82","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/btpr.1565","article-title":"Purification of IgG and albumin from human plasma by aqueous two phase system fractionation","volume":"28","author":"Vargas","year":"2012","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.toxicon.2018.04.002_bib83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/vox.12209","article-title":"Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in\u00a0vitro thrombogenic activity","volume":"108","author":"Vargas","year":"2015","journal-title":"Vox Sang."},{"key":"10.1016\/j.toxicon.2018.04.002_bib84","series-title":"Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products","author":"WHO","year":"2003"},{"key":"10.1016\/j.toxicon.2018.04.002_bib85","series-title":"Recommendations for the Production, Control and Regulation of Human Plasma for Fractionation - World Health Organization","first-page":"941","author":"WHO","year":"2007"},{"key":"10.1016\/j.toxicon.2018.04.002_bib86","series-title":"WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins","author":"WHO","year":"2010"},{"key":"10.1016\/j.toxicon.2018.04.002_bib87","series-title":"WHO Guidelines on Good Manufacturing Practices for Blood Establishments - World Health Organization","first-page":"148","author":"WHO","year":"2011"},{"key":"10.1016\/j.toxicon.2018.04.002_bib88","series-title":"WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins - Expert Committee of Biological Standardization 17\u201326 October","author":"WHO","year":"2016"},{"key":"10.1016\/j.toxicon.2018.04.002_bib89","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/trf.12243","article-title":"Dedicated removal of immunoglobulin (Ig) A, IgM, and Factor (F) XI\/activated FXI from human plasma IgG","volume":"54","author":"Wu","year":"2014","journal-title":"Transfusion"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118301296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010118301296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T17:50:15Z","timestamp":1720201815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010118301296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":89,"alternative-id":["S0041010118301296"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.04.002","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What can be learned in the snake antivenom field from the developments in human plasma derived products?","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2018.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}